Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia
Jeffrey E. Lancet(Cornell University), Maria R. Baer(University of Maryland, Baltimore), Ziyang Zhong(Igan Biosciences (United States)), Maher Albitar(Genomic Health (United States)), Ivana Gojo(Johns Hopkins University), Mary Flanagan Quinn, Kapil N. Bhalla(The University of Texas MD Anderson Cancer Center), Alison L. Hannah(CytomX Therapeutics (United States)), Sheila Tighe(Roswell Park Comprehensive Cancer Center), Michael Burton(University of South Florida), Kathryn Kersey(Igan Biosciences (United States))
Cited by 155
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
|Journal of Clinical Oncology|2018|983
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951